We have included the consensus earnings estimates, as well as the stock price and trading history. Be advised that the earnings and revenue estimates may change ahead of the formal reports, and some companies…
Running a screen on Finviz reveals that about two-thirds of the Dow’s 30 components are up by double-digit percentages in 2019. Although five of the 30 components still are basically down so far in…
Tesla has faced a rough 2019 with a fatal autopilot accident and some analysts calling for its demise, but this could all change according to a couple different reports that came public on Friday.
Although Facebook had a rough run in 2018 amid security breaches, congressional hearings, and privacy issues, the company has done significantly better this year. In fact recent reports of Facebook launching its own cryptocurrency…
While many consumers are familiar with the Apple iPad or the Microsoft Surface, Alphabet Inc. (NASDAQ: GOOG) tablets don’t quite measure up. This tech giant has tried again and again with the Nexus and…
Varonis Systems offers a broad range of robust features and unique functionalities that differentiates it from traditional data security offerings via its platform. This firm continues to be in the sweet spot of purchasing…
Ocular Therapeutix shares jumped on Friday after the firm announced that the U.S. Food and Drug Administration (FDA) approved a Supplemental New Drug Application (sNDA) for Dextenza to include the treatment of ocular inflammation…
CarMax released its fiscal first quarter financial results before the markets opened on Friday. The company said that it had $1.59 in earnings per share (EPS) and $5.37 billion in revenue, compared with consensus…
After a recent rally in Bitcoin and with Facebook creating its own cryptocurrency, it seems that cryptocurrency is back in vogue just in time for summer. Jumping on this revitalized trend, Grayscale Investments, a…
Apple released a letter to U.S. trade representative Robert Lighthizer where the iPhone giant detailed that tariffs on its products would ultimately hurt its contribution to the U.S. economy.
Slack Technologies shares have finally come public in their direct listing. This isn’t a typical IPO, like we’ve seen with Grocery Outlets earlier Thursday. Instead Slack has forgone the underwriters and is directly listing…
Grocery Outlet shares entered the market with a bang. The firm priced its shares at $22 apiece, which was above the expected price range of $17 to $19, although shares actually entered the market…
Oracle reported its most recent quarterly results after markets closed Wednesday. Ultimately this was a record quarter for the firm with its shares hitting an all-time high in Thursday’s session. As a result analysts…
Kroger released its fiscal first quarter financial results before the markets opened on Thursday. The grocer said that it had $0.72 in earnings per share (EPS) and $37.3 billion in revenue, compared with consensus…
It’s been a wild ride in 2019. The seasonal theme of “sell in May and go away” passed and seemingly has turned into “Hold your nose and buy in June.” Now the Dow Jones…
Oracle reported its most recent quarterly results after the markets closed on Wednesday. The firm said that it had $1.16 in earnings per share (EPS) and $11.14 billion in revenue, compared with consensus estimates…
Although Facebook had a rough run in 2018 amid security breaches, congressional hearings, and privacy issues, the company has done significantly better this year. In fact recent reports of Facebook launching its own cryptocurrency…
Kroger is scheduled to release its fiscal first quarter financial results before the markets open on Wednesday. The consensus estimates are calling for $0.72 in earnings per share (EPS) and $37.21 billion in revenue.…
Adobe released its fiscal second quarter financial results after the markets closed on Tuesday. Although the stock only made a handy gain in response to earnings, analysts were fairly positive on the stock.
Melinta Therapeutics shares nearly doubled early on Wednesday after the firm announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Baxdela (delafloxacin) for priority review.
